161 related articles for article (PubMed ID: 19398199)
1. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
[TBL] [Abstract][Full Text] [Related]
2. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
[TBL] [Abstract][Full Text] [Related]
3. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
[TBL] [Abstract][Full Text] [Related]
4. Benzopyran sulfonamides as KV1.5 potassium channel blockers.
Lloyd J; Atwal KS; Finlay HJ; Nyman M; Huynh T; Bhandaru R; Kover A; Schmidt J; Vaccaro W; Conder ML; Jenkins-West T; Levesque P
Bioorg Med Chem Lett; 2007 Jun; 17(12):3271-5. PubMed ID: 17462888
[TBL] [Abstract][Full Text] [Related]
5. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
[TBL] [Abstract][Full Text] [Related]
6. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
[TBL] [Abstract][Full Text] [Related]
8. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.
Blass BE; Fensome A; Trybulski E; Magolda R; Gardell SJ; Liu K; Samuel M; Feingold I; Huselton C; Jackson CM; Djandjighian L; Ho D; Hennan J; Janusz JM
J Med Chem; 2009 Nov; 52(21):6531-4. PubMed ID: 19888755
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.
Trotter BW; Nanda KK; Kett NR; Regan CP; Lynch JJ; Stump GL; Kiss L; Wang J; Spencer RH; Kane SA; White RB; Zhang R; Anderson KD; Liverton NJ; McIntyre CJ; Beshore DC; Hartman GD; Dinsmore CJ
J Med Chem; 2006 Nov; 49(24):6954-7. PubMed ID: 17125248
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.
Lloyd J; Finlay HJ; Vacarro W; Hyunh T; Kover A; Bhandaru R; Yan L; Atwal K; Conder ML; Jenkins-West T; Shi H; Huang C; Li D; Sun H; Levesque P
Bioorg Med Chem Lett; 2010 Feb; 20(4):1436-9. PubMed ID: 20097068
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors.
Zhao L; Yang Q; Tang Y; You Q; Guo X
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):462-471. PubMed ID: 35012386
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
13. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
14. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
Guo X; Chen W; Sun H; You Q
Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
[TBL] [Abstract][Full Text] [Related]
15. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
Ford JW; Milnes JT
J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening and electrophysiological evaluation of new chemotypes of K(v)1.5 channel blockers.
Yang Q; Fedida D; Xu H; Wang B; Du L; Wang X; Li M; You Q
ChemMedChem; 2010 Aug; 5(8):1353-8. PubMed ID: 20540065
[TBL] [Abstract][Full Text] [Related]
17. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
[TBL] [Abstract][Full Text] [Related]
18. Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors.
Guo X; Yang Q; Xu J; Zhang L; Chu H; Yu P; Zhu Y; Wei J; Chen W; Zhang Y; Zhang X; Sun H; Tang Y; You Q
Bioorg Med Chem; 2013 Nov; 21(21):6466-76. PubMed ID: 24071446
[TBL] [Abstract][Full Text] [Related]
19. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
[TBL] [Abstract][Full Text] [Related]
20. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
Eldstrom J; Fedida D
J Mol Graph Model; 2009 Oct; 28(3):226-35. PubMed ID: 19713139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
